VERTEX PHARMACEUTICALS INC / MA Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$84.03 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2017-02-23
- VERTEX PHARMACEUTICALS INC / MA income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2015-12-31 was -$74.67M.
- VERTEX PHARMACEUTICALS INC / MA income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2015-09-30 was -$93.82M.
- VERTEX PHARMACEUTICALS INC / MA income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2015-06-30 was -$220.99M.
- VERTEX PHARMACEUTICALS INC / MA income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2015-03-31 was -$198.70M.
- VERTEX PHARMACEUTICALS INC / MA income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2016 was -$84.03M.
- VERTEX PHARMACEUTICALS INC / MA income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2015 was -$588.18M.
- VERTEX PHARMACEUTICALS INC / MA income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2014 was -$741.83M.
- VERTEX PHARMACEUTICALS INC / MA income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2013 was -$503.62M, a 1660.60% decline from fiscal 2012.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2016-12-31 | -$84.03M 10-K · filed 2017-02-23 | |||
| 2015-12-31 | -$74.67M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$168.49M derived: sum of 2 quarters · filed 2017-02-23 | -$389.48M derived: sum of 3 quarters · filed 2017-02-23 | -$588.18M 10-K · filed 2017-02-23 |
| 2015-09-30 | -$93.82M 10-Q · filed 2015-10-30 | -$314.81M derived: sum of 2 quarters · filed 2015-10-30 | -$513.51M 10-Q · filed 2015-10-30 | -$694.15M derived: sum of 4 quarters · filed 2016-02-16 |
| 2015-06-30 | -$220.99M 10-Q · filed 2015-08-04 | -$419.70M 10-Q · filed 2015-08-04 | -$600.33M derived: sum of 3 quarters · filed 2016-02-16 | -$770.33M derived: sum of 4 quarters · filed 2016-02-16 |
| 2015-03-31 | -$198.70M 10-Q · filed 2015-05-04 | -$379.34M derived: sum of 2 quarters · filed 2016-02-16 | -$549.34M derived: sum of 3 quarters · filed 2016-02-16 | -$708.43M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-12-31 | -$180.64M 10-K · filed 2016-02-16 | -$350.63M derived: sum of 2 quarters · filed 2016-02-16 | -$509.72M derived: sum of 3 quarters · filed 2016-02-16 | -$741.83M 10-K · filed 2017-02-23 |
| 2014-09-30 | -$170.00M 10-K · filed 2016-02-16 | -$329.08M derived: sum of 2 quarters · filed 2016-02-16 | -$561.20M 10-Q · filed 2015-10-30 | -$582.12M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-06-30 | -$159.09M 10-K · filed 2016-02-16 | -$391.20M 10-Q · filed 2015-08-04 | -$412.12M derived: sum of 3 quarters · filed 2016-02-16 | -$533.58M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-03-31 | -$232.11M 10-K · filed 2016-02-16 | -$253.03M derived: sum of 2 quarters · filed 2016-02-16 | -$374.49M derived: sum of 3 quarters · filed 2016-02-16 | -$428.84M derived: sum of 4 quarters · filed 2016-02-16 |
| 2013-12-31 | -$20.92M 10-K · filed 2015-02-13 | -$142.38M derived: sum of 2 quarters · filed 2015-02-13 | -$196.73M derived: sum of 3 quarters · filed 2015-02-13 | -$503.62M 10-K · filed 2016-02-16 |
| 2013-09-30 | -$121.45M 10-K · filed 2015-02-13 | -$175.81M derived: sum of 2 quarters · filed 2015-02-13 | -$482.70M derived: sum of 3 quarters · filed 2015-02-13 | |
| 2013-06-30 | -$54.35M 10-K · filed 2015-02-13 | -$361.25M derived: sum of 2 quarters · filed 2015-02-13 | ||
| 2013-03-31 | -$306.90M 10-K · filed 2015-02-13 | |||
| 2012-12-31 | $32.27M 10-K · filed 2015-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |